An observational study in Advanced Solid Tumor and Lymphoma, sponsored by Oncology Institute of Southern Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Oncology Institute of Southern Switzerland · Observational
Among 71 studies in Lymphoma with a site in Switzerland — 6 open to participants now, 11 under way, 5 of them phase 3. Lymphoma · Switzerland.
Among the 71 studies in Lymphoma with a site in Switzerland, this one is one of 2 that started in 2020, is one of 5 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 61st registered.
3,018 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
Browse Lymphoma studies →6 of the 71 studies in Lymphoma with a site in Switzerland are open now. Recruiting first, the newest first:
University of Zurich · Sites in Switzerland
Ages 65+
University of Zurich · Sites in Switzerland
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
University of Basel · Sites in Switzerland
Ages 6–18
Nurix Therapeutics, Inc. · Sites in Switzerland, United States, France and 5 more countries
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 347 Lymphoma studies recruiting now, 227 (65%) set no upper age limit and 79 (23%) stop at 75 or younger; 78 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 29
First in 1992; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 167 across 393 observational studies indexed under Lymphoma.
Median enrollment 130 across the 64 interventional studies, 208 across the 5 observational. Of the 54 that completed or were terminated, 10 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 71 have an industry lead sponsor. The 10 most frequent:
Oncology Institute of Southern Switzerland is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Oncology Institute of Southern Switzerland has 1 study filed under Lymphoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Lymphoma with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT06430736Insel Gruppe AG, University Hospital BernPRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab) | 2026-12 |
| NCT04510766Oncology Institute of Southern SwitzerlandTumor Molecular Profiling in Early Phase Clinical Trials | 2026-12-31 |
| NCT05131022Nurix Therapeutics, Inc.A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 71 studies in Lymphoma with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective, single centre, non-interventional exploratory research project that will be conducted on biological material and health-related personal data collected.
Single center, two-parts pilot, prospective study to assess the role of molecular tumor profiling in supporting patient enrollment in early phase clinical trials.
Part A: patients with solid tumors or lymphomas (n=40) who are potential candidates for early phase clinical trials will be offered to have their more recent archival tumor tissue analyzed for the presence of somatic genomic alterations with the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 platform.
Part B: patients who have been enrolled in early phase clinical trials (estimated number: 16-18) will have their archival tumor tissue assessed with HTG EdgeSeq Oncology Biomarker Panel Assay for RNA-Seq to explore gene expression signatures and blood collected and stored to create a repository of samples (¨liquid biopsy¨) for future research with the aim to investigate the mutational profile of ctDNA at baseline and the acquisition of new mutations at the time of disease progression as a consequence of treatment exposure.
Patients with histological diagnosis of advanced solid tumor or lymphoma who are potential candidates for early phase clinical trials
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Upon confirmation of the suitability for NGS analysis of the selected tumor sample, tumor DNA will be extracted and molecular profile will be performed using the pan-cancer NGS Ion TorrentTM OncomineTM Comprehensive Assay v3 according to manufacturer's instructions
FFPE tumor archival tissue will be used to perform RNA-Seq with NGS HTG EdgeSeq Oncology Biomarker Panel Assay using the HTG machine following the manufacture's protocol. Blood samples for "liquid biopsy" will be collected at two time points: 1) Any time after enrollment in an early clinical trial and before starting the investigational agent (1 x 10 ml blood sample in EDTA tube as source of normal DNA for comparative analysis; 2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection; 2) At the time of radiological or clinical tumor progression (2 x 10 ml blood samples in cell-free DNA BCT Tubes for ctDNA collection). Blood samples will be collected and stored to create a biobank of "liquid biopsy" for future analysis.
Accrual rate in early phase clinical trials
Number of patients with available molecular profile enrolled per year
Time frame: Two years
Clinical Outcome
Response rate among patients with available molecular tumor profiling that have been enrolled in an early phase clinical trial
Time frame: Two years
Number of successful NGS-based DNA analysis performed on archival tissue
Type and frequency of mutations identified on archival tissue
Time frame: Two years
Number of NGS-based RNA-seq samples analyzed
Analysis performed on archival tissue
Time frame: Two years
Rate of stored samples
Number of blood samples collected and stored for ctDNA analysis
Time frame: Two years
Started Oct 2020 (actual). Primary completion is estimated for Dec 2026, 74 months after the start.
Of 140 non-industry observational studies under Lymphoma, half reached primary completion within 90 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 269. This study's planned 74 months is below that.
Counting every sponsor, half of 159 studies reached it within 82 months; a quarter within 39 and three quarters within 269.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oncology Institute of Southern Switzerland